Imperva Inc (NYSE:IMPV) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.78-0.82 for the period, compared to the Thomson Reuters consensus estimate of $0.45. The company issued revenue guidance of $319.8-322.8 million, compared to the consensus revenue estimate of $321.31 million.Imperva also updated its Q3 guidance to $0.22-0.26 EPS.
Imperva Inc (NYSE:IMPV) traded down 6.54% on Friday, hitting $45.05. 1,546,678 shares of the company traded hands. The stock’s market cap is $1.52 billion. The stock’s 50-day moving average is $48.94 and its 200 day moving average is $45.08. Imperva Inc has a 12 month low of $34.40 and a 12 month high of $57.24.
Imperva (NYSE:IMPV) last issued its earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. The firm had revenue of $74.44 million during the quarter, compared to analysts’ expectations of $74.30 million. Imperva had a net margin of 31.92% and a return on equity of 36.67%. The firm’s revenue was up 28.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.23) EPS. Equities research analysts expect that Imperva Inc will post $0.45 earnings per share for the current fiscal year.
IMPV has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Imperva from a hold rating to a sell rating in a report on Tuesday, July 11th. Stifel Nicolaus reissued a hold rating and set a $47.00 price objective on shares of Imperva in a report on Friday, July 14th. UBS AG initiated coverage on shares of Imperva in a report on Tuesday, June 6th. They set a positive rating and a $60.00 price objective on the stock. Evercore ISI set a $56.00 price objective on shares of Imperva and gave the stock a buy rating in a report on Friday. Finally, Monness Crespi & Hardt boosted their price objective on shares of Imperva from $55.00 to $57.00 and gave the stock a buy rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. Imperva currently has an average rating of Hold and an average price target of $50.39.
In other news, insider Amichai Shulman sold 3,089 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $48.70, for a total value of $150,434.30. Following the completion of the transaction, the insider now owns 100,151 shares of the company’s stock, valued at $4,877,353.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CRO Michael D. Mooney sold 52,356 shares of the business’s stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the completion of the transaction, the executive now directly owns 52,356 shares of the company’s stock, valued at approximately $2,487,433.56. The disclosure for this sale can be found here. Insiders sold 60,302 shares of company stock worth $2,875,861 in the last ninety days. Insiders own 2.20% of the company’s stock.
About Imperva
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.
